Blogs

Plan for Consolidating FDA’s Adverse Event Reporting Systems: Good Idea but Easier Said than Done

Read more
chevron_right

NEW WHITE PAPER: Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (Preprint)

Multistakeholder collaboration, led by Catalyst Healthcare Consulting, to Recommend Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (preprint).

Read more
chevron_right

Catalyst Driving Discussions to Accelerate C&GT Trials: DIA 2025

Read more
chevron_right

Catalyst to attend FDLI 2025 Annual Conference

If you are attending the FDLI conference, we would love to chat - reach out to us on LinkedIn!

Read more
chevron_right

Catalyst advances women’s health in new LinkedIn article

On Tuesday, Catalyst’s Taryn Serman and Nancy Myers, together with industry leaders, published the following article regarding women’s health on LinkedIn.

Read more
chevron_right

Government Shutdown 101: What to Expect

March 14th is approaching fast, and it increasingly looks like politicians are driving us toward another government shutdown.

Read more
chevron_right

Expected FDA Impact of a Government Shutdown

Critically, the critical public health mission and user fees are the buffer for FDA when a shutdown occurs. Below, we will delve into how a shutdown may look for the FDA under the Trump administration.

Read more
chevron_right